Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment (Q37472064)

20 August 2017

1 reference

title

Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment (English)

1 reference

20 August 2017

main subject

cardiovascular disease

1 reference

2

Darren K McGuire

1 reference

20 August 2017

Shiny Mathewkutty

1

1 reference

20 August 2017

publication date

1 May 2009

1 reference

Expert Review of Cardiovascular Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

7

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

541-549

1 reference

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

20 August 2017

cites work

1 reference

Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes

21 January 2018

1 reference

Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention

21 January 2018

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

21 January 2018

1 reference

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents

21 January 2018

1 reference

Platelet dysfunction in type 2 diabetes

21 January 2018

1 reference

Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis

21 January 2018

1 reference

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

21 January 2018

1 reference

Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin

21 January 2018

1 reference

Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial

21 January 2018

1 reference

Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, si

21 January 2018

1 reference

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

21 January 2018

1 reference

Role of mean platelet volume in triagging acute coronary syndromes.

21 January 2018

1 reference

Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate

21 January 2018

1 reference

Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus

21 January 2018

1 reference

The platelet in diabetes: focus on prevention of ischemic events

21 January 2018

1 reference

Aspirin and clopidogrel resistance: an emerging clinical entity

21 January 2018

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

Aspirin and clopidogrel resistance

21 January 2018

1 reference

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

Aspirin resistance and diabetes mellitus

21 January 2018

1 reference

Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases

21 January 2018

1 reference

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome

21 January 2018

1 reference

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

21 January 2018

1 reference

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

21 January 2018

1 reference

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

21 January 2018

1 reference

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

21 January 2018

1 reference

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

21 January 2018

1 reference

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

21 January 2018

1 reference

Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).

21 January 2018

1 reference

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

21 January 2018

1 reference

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

21 January 2018

1 reference

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

Platelet function assessment to predict outcomes after coronary interventions: hype or hope?

21 January 2018

1 reference

Tackling the diabetic platelet: is high clopidogrel dosing the answer?

21 January 2018

1 reference

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

21 January 2018

1 reference

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

21 January 2018

1 reference

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERC.09.30

1 reference

20 August 2017

1 reference